Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series A round brings $25mm to Kyverna

Executive Summary

Kyverna Therapeutics raised $25mm through its Series A round from investors including Vida Ventures, Westlake Village BioPartners, and Gilead Sciences. The company was formed in 2018 and is developing treatments for serious autoimmune diseases based on its T-cell engineering and synthetic biology technologies. Concurrent with the Series A, Kyverna also announced a new deal with Gilead under which Kyverna will use its platforms to discover and develop T-cell therapies, to which Gilead will hold licensing options.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies